Searchable abstracts of presentations at key conferences in endocrinology

ea0011p539 | Endocrine tumours and neoplasia | ECE2006

Multiple endocrine neoplasia type 1 and angiomyxoma

Kostoglou-Athanassiou I , Athanassiou P , Thomas D , Mytakidis N , Vassiliou E , Liakos V , Kaldrymidis Ph

The presence of lipomas is a characteristic of the syndrome of multiple endocrine neoplasia type 1. The presence of myxomas, however, is a characteristic of Carney syndrome.The aim of the study is the description of a patient with the syndrome of multiple endocrine neoplasia type 1 who presented with a malignant angiomyxoma.A male patient, aged 42 years, presented with intense gastric complaints and was diagnosed with a gastroduode...

ea0011p538 | Endocrine tumours and neoplasia | ECE2006

High performance liquid chromatography (HPLC) in the follow-up of mitotane therapy in a patient with adrenal carcinoma

Thomas D , Kostoglou-Athanassiou I , Bournazos S , Mytakidis N , Liakos V , Vassiliou E , Athanassiou P , Kaldrymidis Ph

Adrenal carcinoma is a rare neoplasm with poor prognosis. Mitotane (o,p′-DDD) is the only known therapeutic agent with action on the adrenal. Although it has been used for many decades, its pharmacological properties and exact mechanism of action are still debated. It has been suggested that its therapeutic effect is dose-dependent (Baudin et al 2001). High performance liquid chromatography (HPLC) has been used for the exact measurement of mitotane dose.<p cla...

ea0011p928 | Thyroid | ECE2006

Rate of decrease in antithyroid antibody levels after therapeutic intervention in patients with thyroid cancer

Thomas D , Kostoglou-Athanassiou I , Vassiliou E , Liakos V , Mytakidis N , Chatzimarkou F , Athanassiou P , Kaldrymidis Ph

The detection of antithyroid antibodies, specifically of antithyroglobulin antibodies, in patients with differentiated thyroid carcinoma after near-total thyroidectomy, radioiodine therapy and thyroxine suppression presents difficulties in screening patients for residual disease or recurrence of the disease as it may interfere with thyroglobulin measurement. The aim of the study was to estimate the rate of decrease in antithyroid antibody levels in patients with differentiated...

ea0011p512 | Endocrine tumours and neoplasia | ECE2006

Mutation at codon 804 detected in a Greek kindred by screening of the RET gene in patients with medullary thyroid carcinoma

Mytakidis N , Vassiliou E , Liakos V , Papagrigoriou L , Hadzimarkou F , Kostoglou-Athanasiou I , Koutsodontis G , Ladopoulou A , Bei T , Yannoukakos D , Kaldrymidis P

Medullary Thyroid Carcinoma (MTC) is a rare cancer that arises from the thyroid C-cells and occurs as sporadic in 75% of the cases. In 25% of MTC cases, mutations of the RET proto-oncogene are responsible for the development of three dominantly inherited neoplastic disorders including multiple endocrine neoplasia (MEN) 2A, MEN 2B and familial medullary thyroid carcinoma (FMTC). Since 2–8% of MTC cases considered sporadic conceal germline mutations, direct analysis of the ...

ea0011p513 | Endocrine tumours and neoplasia | ECE2006

A rare RET gene mutation is found in two apparently unrelated Greek kindreds with familial medullary thyroid carcinoma

Mytakidis N , Zachariou M , Anagnostopoulos T , Vassiliou E , Thomas D , Tertipi A , Rampias T , Konstantopoulou I , Natsis P , Yannoukakos D , Kaldrymidis P

Familial medullary thyroid carcinoma (FMTC) is caused by germ-line mutations in the RET proto-oncogene. These mutations concern mainly exons 10 and 11, whereas mutations in exons 13–16 are rare. Mutations in exon 8 have been reported in the literature only twice.We performed direct analysis of exons 7–19 and 21 of RET gene in two apparently unrelated Greek index-patients with FMTC, presenting negative initial screening for mutations in exons 10...